Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758598 | 0.84 | HDAC1 (0.50) | HDAC1HDAC8HDAC6ABCB1ABCC1 | |
| SCHEMBL5119297 | 0.81 | HDAC1 (0.51) | HDAC1HDAC8HDAC6ABCB1ABCC1 | |
| SCHEMBL4826786 | 0.81 | DRD2 (0.54) | HDAC1HDAC8HDAC6ALDH1A1KMT2A | |
| SCHEMBL5117052 | 0.79 | HDAC1 (0.56) | HDAC1HDAC8HDAC6ABCB1ABCC1 | |
| SCHEMBL1051719 | 0.76 | NOTUM (0.51) | NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL14266177 | 0.75 | SMN1; SMN2 (0.54) | HDAC1HDAC8HDAC6ABCB1ABCC1 | |
| SCHEMBL1051422 | 0.75 | HDAC1 (0.46) | HDAC1HDAC8HDAC6NOTUM | |
| SCHEMBL2223682 | 0.75 | LMNA (0.52) | HDAC1HDAC8HDAC6NOTUMSMN1; SMN2 | |
| SCHEMBL12744497 | 0.74 | ENPP3 (0.54) | HDAC1HDAC8HDAC6ABCB1ABCC1 | |
| SCHEMBL1049840 | 0.74 | NOTUM (0.46) | NOTUMALDH1A1HSD17B10KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872034-B2 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| CN-100439347-C | 4- (3- (2-phenyloxazol-4-ylmethoxy) -cyclohexyloxy) -butyric acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis | SANNOFFE AVENTIS PHARMA GMBH (DE) | 2008-12-03 | — | — | CN | disclosed |
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-7335671-B2 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-26 | — | — | US | disclosed |
| CN-1753881-A | 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis. | SANNOFFE AVENTIS PHARMA GMBH (DE) | 2006-03-29 | — | — | CN | disclosed |
| US-20040209920-A1 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, FFAR1, FFAR2 | HDAC1 4321/4885HDAC8 4153/4885HDAC6 4235/4885 |
| US-20040209920-A1 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, FFAR1, FFAR2 | HDAC1 4194/4885HDAC8 4287/4885HDAC6 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.